Treating SCLC in the Relapsed/Refractory Setting: Giving Patients a Voice About Second-Line Therapy

Interactive Practice Guide

SCLC is aggressive in nature with a high recurrence rate following initial treatment and a propensity to become resistant to conventional therapies. Early detection is critical, but many patients are diagnosed at an advanced stage where prognosis is poor. Progress in the second-line setting offers new hope for improving patient outcomes, but the rapid pace at which these advances are occurring present challenges for effectively integrating novel therapies into patient care. In fact, research shows that oncologists may not be offering second-line therapies to patients with SCLC despite good functional status. To help clinicians enhance their diagnostic-therapeutic paradigms for SCLC, this practice guide interweaves education and practical guidance for easy integration of the latest evidence-based strategies into daily clinical processes and workflows.

Faculty: Firas Badin, MD, Carl Gay, MD

Release Date: September 15, 2024

Expiration Date: September 15, 2025